Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
Appointed director
|
|
PaxMedica, Inc.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 09/27/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 08/21/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/17/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 08/16/2023 |
8-K
| Resignation/termination of a director |
| 08/09/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/09/2023 |
8-K
| Quarterly results|
Docs:
|
"PaxMedica, Inc. Announces Second Quarter 2023 Financial Results and Business Update TARRYTOWN, NY, August 9, 2023– PaxMedica, Inc. , a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms, today provided a business update and reported financial results for the second quarter 2023, ended June 30, 2023. Recent Highlights · Announced positive top line results from the PAX-101 Phase 3 African Sleeping Sickness Study, PAX-HAT-301, paving the way for an expected NDA filing in 2024 · Granted Exclusive Pharmacy Distribution Rights for PAX-101 to Vox Nova, LLC, the first purpose-built limited distribution specialty pharmacy benefit manager for people with autism ..." |
|
| 08/04/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 07/24/2023 |
8-K
| Quarterly results |
| 07/06/2023 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
| 06/16/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 06/08/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 06/02/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 05/15/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/15/2023 |
8-K
| Quarterly results|
Docs:
|
"PaxMedica, Inc. Provides First Quarter 2023 Business Update; Phase 3 HAT-301 Top Line Results Expected in Second Half 2023 Tarrytown, N.Y. May 15, 2023 - PaxMedica, Inc. , a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms, today provided a business update and reported financial results for the first quarter 2023 ended March 31, 2023. Howard Weisman, Chief Executive Officer of PaxMedica, commented, “During the first quarter we’ ve continued working hard to advance the ongoing retrospective Phase 3 HAT-301 trial and we continue to expect to announce top line results in the second half of 2023. The study, if successful, is expected to lead to the submission of a New..." |
|
| 05/12/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 05/11/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 04/24/2023 |
DEFR14A
| Form DEFR14A - Revised definitive proxy soliciting materials: |
| 04/06/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/06/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 03/31/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 02/07/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 02/07/2023 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...|
Docs:
|
"THIS NOTE HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED , AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY. THIS NOTE AND THE SECURITIES ISSUABLE UPON CONVERSION OF THIS NOTE MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOU...",
"COMMON STOCK PURCHASE WARRANT",
"SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement is entered into as of February 2, 2023, by and between PaxMedica, Inc., a Delaware corporation , and Lind Global Fund II LP, a Delaware limited partnership . BACKGROUND A. The board of directors of the Company has authorized the issuance to Investor of the Note and the Warrant . B The Investor desires to purchase the Note and the Warrant on the terms and conditions set forth in this Agreement. C. Concurrently with the execution of this Agreement, the Company and the Investor will enter into a security agreement, substantially in the form attached hereto as , pursuant to which the Company will grant a first priority security interest in substantially all of the assets of the Company to secure its obligations hereunder and unde...",
"[Signature pages to follow]" |
|
| 01/06/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 01/06/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 12/19/2022 |
S-1
| Form S-1 - General form for registration of securities under the Securities Act of 1933: |
| 12/19/2022 |
8-K
| Quarterly results |
| 12/09/2022 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 11/21/2022 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Departure of Directors or Certain Office...|
Docs:
|
"WHEREAS: Subject to the terms and conditions set forth in this Agreement, the Company wishes to sell to the Investor, and the Investor wishes to buy from the Company, up to Twenty Million Dollars of the Company’ s common stock, $0.0001 par value per share . The shares of Common Stock to be purchased hereunder are referred to herein as the " Purchase Shares ." NOW THEREFORE, in consideration of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Company and the Investor hereby agree as follows: 1. CERTAIN DEFINITIONS. For purposes of this Agreement, the following terms shall have the following meanings: " Accelerated Purchase Date " means, with respect to any Accelerated Purchase made...",
"REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT , dated as of November 17, 2022, is entered into by and between PAXMEDICA, INC., a Delaware corporation , and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company . Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the Purchase Agreement by and between the parties hereto, dated as of the date hereof . WHEREAS: A. Upon the terms and subject to the conditions of the Purchase Agreement, the Company has agreed to issue to the Investor, and the Investor has agreed to purchase, up to Twenty Million Dollars of the Company's common stock, par value $0.0001 per share , pursuant to the Purchase Agreement , and the Company has agreed to issue to the Investor s...",
"EMPLOYMENT AGREEMENT",
"PaxMedica, Inc. Enters into Committed Equity Investment Agreement for up to $20 Million with Lincoln Park Capital" |
|
| 11/08/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 10/12/2022 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 10/03/2022 |
8-K
| Quarterly results |
| 09/30/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 09/26/2022 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
| 09/09/2022 |
SC 13D
| TardiMed Sciences LLC reports a 63.4% stake in PAXMEDICA, INC. |
|
|
|